AU Patent

AU2022246021A1 — Glycan-mediated protein degradation

Assigned to Glycoera Ag · Expires 2023-10-05 · 3y expired

What this patent protects

The present disclosure provides glycoengineered bifunctional binding proteins for glycan-mediated degradation. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such glycoengineered bifunctional binding protein…

USPTO Abstract

The present disclosure provides glycoengineered bifunctional binding proteins for glycan-mediated degradation. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such glycoengineered bifunctional binding proteins are useful for treating and preventing various diseases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022246021A1
Jurisdiction
AU
Classification
—
Expires
2023-10-05
Drug substance claim
No
Drug product claim
No
Assignee
Glycoera Ag
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.